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Abstract Hemorrhage is common in brain tumors. Due
to characteristic magnetic field changes induced by he-
mosiderin it can be detected using susceptibility weighted
MRI (SWI). Its relevance to clinical syndromes is unclear.
Here we investigated the patterns of intra-tumoral SWI
positivity (SWIpos) as a surrogate for hemosiderin with
regard to the prevalence of epilepsy. We report on 105
patients with newly diagnosed supra-tentorial gliomas and
brain metastasis. The following parameters were recorded
from pre-operative MRI: (1) SWIpos defined as dot-like or
fine linear signal changes; (2) allocation of SWIpos to tumor
compartments (contrast enhancement, central hypointensi-
ty, non-enhancing area outside contrast-enhancement); (3)
allocation of SWIpos to include the cortex, or SWIpos in
subcortical tumor parts only; (4) tumor size on T2 weighted
and gadolinium-enhanced T1 images. 80 tumors (76 %)
showed SWIpos (4/14 diffuse astrocytoma WHO II, 5/9
anaplastic astrocytoma WHO III, 41/46 glioblastoma WHO
IV, 30/36 metastasis). The presence of SWIpos depended on
tumor size but not on patient’s age, medication with
antiplatelet drugs or anticoagulation. Seizures occurred in
60 % of patients. Cortical SWIpos significantly correlated
with seizures in brain metastasis (p = 0.044), and as a
trend in glioblastoma (p = 0.062). Cortical SWIpos may
confer a risk for seizures in patients with newly diagnosed
brain metastasis and glioblastoma. Whether development
of cortical SWIpos induced by treatment or by the natural
course of tumors also leads to the new onset of seizures has
to be addressed in longitudinal studies in larger patient
cohorts.
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Introduction
Intra-tumoral hemorrhage is frequent in brain tumors.
Histopathological studies report on an incidence of 13 % in
glioblastoma, and of 30 % in oligodendrogliomas [1]. Also
brain metastases show hemorrhage which is present in up
to 36 % of patients [1]. Acute hemorrhage can result in
stroke-like symptoms [1]. On the other hand blood pro-
ducts such as iron and hemosiderin are epileptogenic which
has been demonstrated in animal models and patients with
vascular malformations [2–4]. Seizures are among the
presenting symptoms in 30–50 % of patients with newly
diagnosed tumors, and develop in up to 30 % during the
post-operative course of disease [5]. A role for hemosiderin
in the epileptogenesis of brain tumors has been postulated,
however this was not yet addressed in detail [6]. As the
above mentioned data on the incidence of intra-tumoral
hemorrhage were derived from surgically obtained tis-
sue specimen they do not allow to describe the exact intra-
tumoral localization of hemorrhage [1]. Using
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susceptibility-weighted magnetic resonance imaging (SWI)
it is possible to detect signal abnormalities compatible with
deposits of blood products such as hemosiderin in vivo
(SWI positivity, SWIpos) [7]. This technique therefore
enables to characterize SWIpos within tumors compart-
ments as well as in the cortical and subcortical brain areas
involved by the tumor. The aim of our study was to
describe the incidence and distribution of SWIpos in newly
diagnosed brain tumors, and to assess whether distinct
patterns of SWIpos relate to the occurence of seizures.
Materials and methods
Clinical data
We retrospectively analyzed all successive patients with
newly diagnosed supra-tentorial low and high grade glioma
and brain metastasis which were treated at our institution
between January 2009 and July 2012. As SWIpos can be
found due to both the presence of blood products and
calcification we excluded oligodendroglial tumors where
calcification is frequently observed [7]. Patient charts were
reviewed with regard to age at diagnosis of brain tumor,
gender, and to the presence and semiology of seizures.
Medication was recorded with particular emphasis on the
administration of platelet inhibitors (aspirin, clopidogrel)
or warfarin. The study was approved by the local ethics
committee.
MRI data acquisition
All MR images were obtained as our routine standard
diagnostic procedure in patients suspected to suffer from
brain tumor using a 1.5 T Avanto or Espree scanner (Sie-
mens Healthcare, Erlangen, Germany) using an eight
channel head array coil. Among our routine MR imaging
protocol of the brain which includes contrast- (Gadovist)
enhanced T1-weighted images an axial SWI sequence was
obtained, which is a combination of magnitude and phase
images of a 3D velocity compensated gradient echo
sequence. The parameters of the T2 SWI were as follows:
acquisition time 4:38 min, slice thickness 2 mm, TE/
TR = 40/40 ms, 1 average and flip angle of 15.
MRI data analysis
Pre-operative MRI scans were analyzed. SWIpos was
defined using the following procedure: (1) the SWI
sequences were used to detect dot-like or fine linear hyp-
ointense signal changes (SWIpos) [8]; (2) the minimum
Intensity Projection (mIP) of the SWI sequences was
reviewed to ensure that tumor signal changes are not due to
flow signal from vessels; (3) the Phase imaging sequences
were used to exclude calcification as a source of intra-
tumoral SWIpos [7]. In patients with multiple brain
metastases and focal epilepsy the lesion compatible with
seizure semiology was chosen for assessment of SWIpos. In
patients without seizures the largest brain metastasis was
chosen.
As there are no established criteria to classify the degree
of SWIpos we arbitrarily defined three categories: grade
0 = no SWIpos, grade I = one to five focal signal changes
(either dot-like or fine linear or both), grade II = C six
focal signal changes [8].
SWIpos was also characterized by its cortical and/or
subcortical localization. In patients with contrast-enhanc-
ing tumors we further assessed whether SWIpos involved
the enhancing tumor area, the central hypointensity within,
or the non-enhancing area outside contrast-enhancement.
Tumor size was measured on axial contrast-enhanced T1
and T2 weighted images according to the RANO criteria
[9]. The two maximal perpendicular diameters were cal-
culated on the plane showing the largest tumor diameter. In
patients with multiple brain metastases the lesion which
corresponded to the focal seizure semiology was chosen. In
patients without seizures the largest lesion was chosen.
Statistics
We tested whether SWIpos was associated with age, treat-
ment with platelet inhibitors or warfarin, or with tumor
size. For comparison of categorial or continuous variables
the Fisher’s exact and Chi square test was applied. We used
regression analysis to estimate whether the presence of
seizures was associated with any of the clinical character-
istics and imaging results. Statistical analyses were per-
formed using SigmaStat 12 Software, SyStat, Inc., USA.
Results
We identified 105 patients (68 male, 37 female, age
59.5 ± 12.3 years (mean ± SD) with newly diagnosed
brain tumors (14 low-grade glioma WHO II, 9 anaplastic
glioma WHO III, 46 glioblastoma WHO IV, 36 brain
metastasis) (Table 1). The histopathological diagnosis was
established in 91 % by partial or gross total resection, 9 %
of patients were biopsied only. 87 % of patients with brain
metastasis suffered from multiple lesions. 25 patients
(24 %) received platelet inhibitors or warfarin for cardio-
vascular disorders. All glioblastomas and brain metastases
showed blood–brain barrier (BBB) disruption to a variable
degree as evident on pre-operative gadolinium-enhanced
MRI. Two low-grade gliomas and five anaplastic gliomas
showed circumscribed BBB disruption.
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Frequency and distribution of SWIpos
SWIpos was observed in 80 patients (76 %) and was sig-
nificantly higher in glioblastoma and brain metastasis
compared to the other subgroups (Chi square 9.455,
p = 0.024) (Table 1). The distribution of SWIpos within
the tumors and with regard to subcortical location and
cortical involvement is illustrated in Fig. 1. In the majority
Table 1 Clinical data and imaging results
Histology n Agea PI
Warf
Tumor size
(T1 ? CEb)a
Tumor size
(T2b)a
SWIpos
tumors
SWIpos located
in BBBDd
years % mm2 mm2 n (%) %
Low-grade glioma 14 53 ± 12 14 3.1 ± 1.6 20.5 ± 14.1 4 (29) 50
Anaplastic astrocytoma 9 58 ± 15 44 4.8 ± 8.4 21.2 ± 11.0 5 (56) 100
Glioblastoma 46 59 ± 12 15 13.6 ± 8.6 29.9 ± 15.7 42 (91) 90
Brain metastasisc 36 63 ± 11 33 7.5 ± 8.0 19.5 ± 12.9 29 (83) 97
a Data are presented as mean ± SD. PI, Warf: percentage of patients receiving platelet inhibitors or warfarin
b T1 ? CE = contrast enhanced T1-weighted MRI; T2 = T2-weighted MRI; SWIpos: MRI susceptibility changes compatible with the presence
of hemosiderin (see ‘‘Materials and methods’’ section)
c Primary tumor: small cell lung cancer (n = 4), non-small cell lung cancer (n = 13), breast cancer (n = 5), malignant melanoma (n = 4),
prostate (n = 2), urothel (n = 2), colon (n = 1), esophagus (n = 1), uterus (n = 1), unknown (n = 3)
d BBBD: tumor area with blood–brain barrier disruption and/or central hypointensity
a b c
d e f
Fig. 1 Distribution of hemosiderin in newly diagnosed brain tumors.
Fibrillary astrocytoma (left), glioblastoma (middle), brain metastasis
(right). Top a–c intra-tumoral SWIpos. Bottom T2 weighted (d) and
gadolinium enhanced T1 weighted (e, f) MRI. Arrow subcortical (a,
b) and cortical (c) SWIpos
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of patients with malignant tumors SWIpos was located to
the area of BBB disruption or the central hypointensity and
was of grade II (Tables 1, 2). SWIpos significantly corre-
lated with tumor size on T2 weighted and gadolinium
enhanced T1 MRI (p \ 0.001), but neither with patient’s
age (p = 0.371) nor with treatment with platelet inhibitors
or warfarin (p = 0.290).
Seizures, tumor size and SWIpos
For the whole group of 105 patients the presence of sei-
zures correlated with tumor size on MRI T2 and gadolin-
ium enhanced T1 weighted MR (p = 0.009, 0.002), but not
with age (p = 0.127) and medication with platelet inhibi-
tors or warfarin (p = 0.423). SWIpos revealed a significant
correlation with seizures as onset symptoms (p = 0.005,
likelihood ratio 0.62), but with moderate sensitivity (0.5)
and specificity (0.2) (Fisher’s exact test). A stronger
association with seizures was observed when SWIpos
involved the cerebral cortex (p = 0.003, likelihood ratio
2.2). Here we found a sensitivity of 0.67 and a specificity of
0.7. Involvement of the cortex by tumor alone was of
marginal significance (p = 0.051).
SWIpos with regard to seizures in the histological sub-
groups is detailed in Table 2 and is summarized in Fig. 2.
Seizure frequency and cortical involvement by tumor was
highest in low-grade glioma, but cortical SWIpos was lowest
in this subgroup (Fig. 2). Vice versa 95 and 77 % of patients
with glioblastoma and brain metastasis showed cortical
involvement by tumor, but only 65 and 73 % showed cor-
tical SWIpos, and 43 and 72 % of these patients experienced
seizures. Testing all clinical and imaging variables we
observed a significant correlation between cortical SWIpos
and the presence of seizures for brain metastasis
(p = 0.044), and a trend for glioblastoma (p = 0.062).
Tumor SWIpos per se did not correlate with the presence of
seizures. Logistic regression analysis was not possible for
low-grade glioma and anaplastic astrocytoma due to the
small number of patients in these subgroups. The Chi square
test showed no correlation between the grade of SWIpos and
the presence of seizures in all subgroups (Table 2).
Discussion
Our data indicate that intra-tumoral hemorrhage as studied
with susceptibility weighted MRI (SWIpos) occurs more
frequent than estimated from histopathological analysis [1].
This difference is most likely explained by sampling errors
in patients who underwent partial resection or biopsy only
[1]. In line with earlier reports the incidence of SWIpos
Table 2 SWIpos and seizures
Histology Presence
of seizures
n (%)
SWIpos in tumor
subgroups
n (%)
Grade of
SWIpos (0/1/2)
a
n
Tumor involves
cortex
n (%)
Tumors with
cortical SWIpos
n (%)
Low-grade glioma Yes 13 (93) 4 (31) 9/2/2 13 (100) 3 (23)
No 1 (7) 0 (0) 1/0/0 0 (0) 0 (0)
Anaplastic astrocytoma Yes 4 (44) 1 (25) 3/1/0 3 (75) 1 (25)
No 5 (56) 4 (80) 1/1/3 5 (100) 2 (40)
Glioblastoma Yes 20 (43) 16 (85) 4/0/16 19 (95) 13 (65)
No 26 (57) 25 (96) 1/1/24 24 (92) 11 (42)
Brain metastasis Yes 26 (72) 21 (81) 5/5/16 20 (77) 19 (73)
No 10 (28) 9 (90) 1/0/9 9 (90) 4 (40)
a The grade of SWIpos did not correlate with seizures (low-grade glioma p = 0.422, anaplastic astrocytoma p = 0.283, glioblastoma p = 0.159,
brain metastasis p = 0.209; Chi square test)
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Fig. 2 Frequency of seizures, cortical involvement by tumor and
cortical SWIpos LGG: low-grade glioma, ANAC: anaplastic astrocy-
toma, GBM: glioblastoma, META: brain metastasis
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exceeded 80 % in patients with glioblastoma and brain
metastasis, and was low in patients with low-grade glioma
[8, 10]. Therefore the presence of SWIpos on MRI may
serve as a non-invasive marker of tumor malignancy. As
the majority of patients with glioblastoma and brain
metastasis show SWIpos within the area of BBB disruption
or the central tumor core it is likely that SWIpos represents
a non-specific marker of vascular leakage common to
malignant brain tumors. The abnormal vascular structure in
malignant gliomas is composed by immature and retiform
capillaries as well as by thin walled sinusoids which may
predispose to hemorrhage [11]. The origin of SWIpos in
non-enhancing low grade glioma is unclear. It may be
hypothesized that circumscribed SWIpos lesions (Fig. 1a)
represent malignant tumor foci, and that the detection of
new or enlarging SWIpos during the long-term course of
low-grade tumors indicates subsequent transformation into
malignant glioma. Biopsy of SWIpos tumor regions aiming
at the detection of malignant glioma may unravel vascular
changes within these lesions.
The overall clinical impact of hemorrhage in brain
tumor patients has not been addressed in detail. Hemor-
rhage with stroke-like symptoms is rare and occurs in 2 to
3 % of patients [1, 12]. These clinical events are clearly
less frequent than the histopathological detection of he-
mosiderin or SWIpos on MRI (our data) [1, 11]. Small intra-
tumoral hemorrhage which does not result in stroke-like
symptoms may be present for a hitherto unknown period of
time. The evolution of the characteristic signal changes due
to hemorrhage has been studied in T1 and T2 weighted
MRI in various conditions including brain tumors [13, 14].
Hemorrhage induced hypointensity on T2 weighted
sequences can be already observed 1 day after bleeding. As
SWI are derived from T2 weighted sequences a similar
behaviour of intra-tumoral SWIpos can be assumed. Intra-
tumoral hemorrhage at the time of tumor detection may
therefore be present for several days or even longer.
Whether single or multiple small intra-tumoral hemor-
rhages contribute to persisting or increasing neurological
dysfunction as e.g. in patients with amyloid angiopathy
cannot be answered at the present time [15]. However
cortical SWIpos in our study was significantly associated
with the presence of seizures in brain metastasis, and as a
trend in glioblastoma. This would be in line with studies in
animals and patients with vascular malformations. Intra-
cortical injection of hemoglobin or ferric chloride in rats
leads to persisting spike activity and seizures which occur 2
to 8 days after injection [2, 3]. In patients with resected
cavernoma areas with hemosiderin deposits show neuronal
loss, glial proliferation and upregulation of NMDA recep-
tor subunits to a magnitude considered to be able to pro-
mote seizures [16]. Accordingly cortical SWIpos may
indicate a role for hemosiderin in the epileptogenicity of
glioblastoma and brain metastasis. It has been proposed
that disruption of the BBB per se induces seizures by
extravasation of albumine and activation of transforming
growth factor beta (TGFb) [17]. Whether this assumption
is relevant to patients with brain tumors has not been
investigated. In our series all patients with glioblastoma or
brain metastasis showed BBB disruption, but only 43 and
72 % respectively experienced seizures. Our findings
therefore do not support the view that BBB disruption or
cortical involvement alone explain the epileptogenicity of
these brain tumors.
Cortical tumor location represented a strong factor
associated with pre-operative seizures in a series of 508
patients with low-grade glioma [18]. In line with this
finding we found in our small subgroup of low-grade gli-
oma patients a high percentage of cortical involvement, but
only few tumors with SWIpos. Therefore biochemical
alterations other than hemosiderin deposits may account
for the occurrence of seizures in these tumors. In general
changes in pH, amino acid composition, NMDA receptor
status have been discussed to be involved in epilepto-
genesis [6]. However, all these metabolic changes cannot
be assessed in a non-invasive manner in human patients.
Therefore they cannot serve as in vivo markers to deter-
mine the risk for seizures. From a methodological point of
view it can be assumed that SWIpos in fact reflects hemo-
siderin if mIP and Phase images exclude tumor calcifica-
tion and flow signal. However, prospective tissue
validation of SWIpos in brain tumors is required. Pre-
liminary data of our group obtained from a retrospective
series indicate a high specificity to identify hemosiderin
using susceptibility weighted MRI [19].
The limitation of our study is the small number of
patients, particularly of low-grade gliomas and anaplastic
astrocytomas, which however reflects their incidence in the
general population and therefore in our clinical routine.
Cortical SWIpos as an independent predictor of subsequent
seizures should lead to re-evaluate the use of prophylactic
anticonvulsants in patients showing this feature. From our
results we propose to longitudinally investigate the pre-
sence and evolution of SWIpos with particular focus on
glioblastoma and brain metastasis in larger patient cohorts.
Several issues may contribute to hemosiderin deposits
during the course of brain tumors. SWIpos is often detected
after brain tumor surgery. Irradiation can result in vascular
leakage and microbleeds [20, 21]. In addition hemorrhage
may also result from anti-angiogenic therapy, uncontrolled
tumor growth and from the appearance of new brain
metastasis. In a recent study on patients with newly diag-
nosed brain metastasis from malignant melanoma 94 % of
lesions involved the cerebral cortex, and 54 % were hem-
orrhagic [22]. In those patients who initially did not present
with seizures the risk to develop seizures within three
J Neurooncol (2013) 115:463–468 467
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months after the time of the diagnosis was 17 % if no
prophylactic anticonvulsants were administered. In contrast
no patient treated with prophylactic anticonvulsants suf-
fered from seizures during that period. It appears worth-
while to prospectively assess whether cortical SWIpos
represents a risk factor for the occurrence of seizures, and
whether cortical SWIpos determines the risk for seizure
relapse once anticonvulsants are discontinued after surgery.
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